Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline...
Clinical Trial
Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or...
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring
Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology...
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a...
Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF)...
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented...
Cardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide...
CelLBxHealth PLC Presents Proof-of-Concept Study
CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics' workflow at world-leading drug development conferenceParsortix platform shown to be compatible with...
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec...
Cryoport Reports Third Quarter 2025 Financial Results
Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3...
Healthcare Analytics Market Size to grow USD 532.75 Billion by 2035, at 25.75% CAGR | Vantage Market Research
NEW YORK, Nov. 4, 2025 /PRNewswire/ -- The Global Healthcare Analytics Market is poised for exponential expansion, rising from USD 42.96 billion...
RO TO PRESENT EIGHT RESEARCH ABSTRACTS AT OBESITYWEEK 2025
Research sheds light on health outcomes and insurance coverage for patients treated with GLP-1s, and how technology is innovating obesity...
President Trumps Two Wars: Drug Cartels Abroad, Marijuana Science at Home – We Must Win Both
The DEA's Double Standard: Raiding Cartels While Blocking CuresThe time has come for Cole's DEA to separate crime from science,...
Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth
Zomedica posts highest quarterly revenue ever and record year-over-year revenue for 19th straight quarter! ANN ARBOR, MI / ACCESS Newswire...
Hemostemix Closes Private Placement of $461,230
Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading...
IgniteData Announces Final Close of Oversubscribed Series A, Led by FCA Venture Partners with the Labcorp Venture Fund and Epsilon as Key Investors
NEW CASTLE, Del., Nov. 4, 2025 /PRNewswire/ -- IgniteData, a leader in intelligent clinical trial data automation, today announced the final...
Global AI-Powered Pathology Market Valued at USD 184 Million in 2023, Set to Grow at 11.7% CAGR Through 2030 | Valuates Reports
BANGALORE, India, Nov. 4, 2025 /PRNewswire/ -- What is the Market Size of AI-Powered Pathology Market? The global AI-Powered Pathology...
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
RALEIGH, N.C. and TEL-AVIV, Israel, Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty...
Dalan Animal Health Announces Successful Efficacy Trials for its Honeybee Vaccine, Advancing Toward Full USDA Licensure
The successful vaccine trials for honeybees, together with recent breakthrough results from clinical trials for disease prevention in shrimp, further...
AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy...